GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Linezolid

Local RX List renal extractBase record retrieved 2026-09-05See the evidence for this drug6 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (6)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

2 additional source qualifications - review before use
Label guidance versus selected expert dose reduction

The label does not require routine renal reduction. UCSF describes a selected strategy for stable patients with CrCl below 30 and an anticipated course longer than 10 days, after the initial 72 hours.

Before applying: Do not apply a reduced regimen universally. Retain the clinical-stability, duration, monitoring and specialist qualifiers.

Linezolid: qualified expert reduction versus label no-adjustment

UCSF describes an optional expert reduction for selected stable patients receiving a prolonged course, rather than a universal renal reduction. Its dialysis table remains separately stated.

Before applying: Document the source and qualifying clinical context; involve infectious diseases and consider drug-level monitoring. Do not apply the expert exception indiscriminately.

Also check: Label guidance versus selected expert dose reduction; Linezolid: qualified expert reduction versus label no-adjustment

Rxlist source

GlobalRPh RX List - ZYVOX

Product / population
Linezolid - ZYVOX renal label; selected renal source sections only, not a complete prescribing monograph.
Renal measure
Qualitative renal impairment; no numeric dose algorithm is inferred.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

Parent linezolid pharmacokinetics do not require renal dose adjustment, but inactive metabolites accumulate as renal function worsens; weigh the uncertain clinical significance against potential risks. The label directs administration after hemodialysis and reports approximately 30% removal in the described three-hour session. Peritoneal-dialysis pharmacokinetics are unavailable. This no-adjustment statement does not eliminate toxicity surveillance.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-08. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/zyvox-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Zyvox

No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Linezolid; parent-drug renal guidance and dialysis timing.

Renal method: Renal impairment categories; no numeric cutoff for label adjustment.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - ZYVOX

No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Linezolid - ZYVOX renal label; selected renal source sections only, not a complete prescribing monograph.

Renal method: Qualitative renal impairment; no numeric dose algorithm is inferred.
Retrieved: 2026-09-08

Read local renal resultOpen original reference
Professional guidance

UCSF - linezolid: standard dose and optional expert reduction

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

Linezolid - UCSF qualified renal guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Linezolid - UCSF qualified renal guidance; selected renal source sections only, not a complete prescribing monograph.

Renal method: Creatinine clearance (CrCl), mL/min; selected passage does not establish an estimating equation.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Linezolid: qualified expert reduction versus label no-adjustment

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

setting specific

Label guidance versus selected expert dose reduction

The label does not require routine renal reduction. UCSF describes a selected strategy for stable patients with CrCl below 30 and an anticipated course longer than 10 days, after the initial 72 hours.

How to use this: Do not apply a reduced regimen universally. Retain the clinical-stability, duration, monitoring and specialist qualifiers.

GlobalRPh RX List - ZyvoxUCSF - linezolid: standard dose and optional expert reduction

Source difference identified; final patient-specific adjudication required.

guideline difference

Linezolid: qualified expert reduction versus label no-adjustment

UCSF describes an optional expert reduction for selected stable patients receiving a prolonged course, rather than a universal renal reduction. Its dialysis table remains separately stated.

How to use this: Document the source and qualifying clinical context; involve infectious diseases and consider drug-level monitoring. Do not apply the expert exception indiscriminately.

GlobalRPh RX List - ZYVOXLinezolid - UCSF qualified renal guidance

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - ZyvoxGlobalRPh RX List - ZYVOXNebraska Medicine: LinezolidUCSF - linezolid: standard dose and optional expert reductionLinezolid - UCSF qualified renal guidance
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/linezolid/

Adult and pediatric dosing

Adult vancomycin-resistant enterococcal infection: 600 mg orally or IV every 12 hours for 14-28 days.

Adult nosocomial pneumonia, community-acquired pneumonia including concurrent bacteremia, and complicated skin/skin-structure infection: 600 mg orally or IV every 12 hours for 10-14 days.

Uncomplicated skin/skin-structure infection: adults, 400 mg orally every 12 hours; adolescents at least 12 years, 600 mg orally every 12 hours; treat for 10-14 days.

Children from birth through 11 years: for complicated skin infection, either listed pneumonia indication, or VRE infection, 10 mg/kg IV or orally every 8 hours. Source durations are 10-14 days for skin/pneumonia and 14-28 days for VRE.

For uncomplicated skin infection: under age 5 years, 10 mg/kg orally every 8 hours; age 5-11 years, 10 mg/kg orally every 12 hours, for 10-14 days.

Preterm neonates with gestational age below 34 weeks and postnatal age below 7 days have lower clearance and higher AUC: begin 10 mg/kg every 12 hours; consider every 8 hours if response is inadequate. By postnatal age 7 days all neonates should receive every-8-hour dosing in the source regimen.

GRPH-linezolid-01 · Source section: Adult and pediatric dosingRenal section finder

GlobalRPh comments

For adult MRSA infection the source gives 600 mg every 12 hours. Oral tablets/suspension and IV treatment are discussed; conversion from IV to oral does not require a dose adjustment.

Among the small number of pediatric cases with MIC 4 micrograms/mL, 5 of 6 (83%) were cured. Pediatric pharmacokinetic variability is wide. In a suboptimal response, consider lower systemic exposure, infection site/severity and underlying illness, especially when MIC is 4 micrograms/mL.

Controlled trials used courses of 7-28 days; the physician determines duration according to response.

GRPH-linezolid-02 · Source section: GlobalRPh commentsRenal section finder

Renal Dosing

No adjustment is listed. The two primary metabolites accumulate in renal impairment; the source states that their clinical significance requires additional study.

GRPH-linezolid-03 · Source section: Renal DosingRenal section finder

Hemodialysis

No dose adjustment. Administer after dialysis on treatment days; approximately 30% is extracted.

GRPH-linezolid-04 · Source section: HemodialysisRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Zyvox

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Linezolid; parent-drug renal guidance and dialysis timing.

Renal method: Renal impairment categories; no numeric cutoff for label adjustment.
Source date: Revised July 2023
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

No renal dose adjustment is recommended because parent-drug concentrations are similar across impairment groups. The two primary metabolites accumulate as renal function declines; weigh the potential risks of that accumulation. Administer after hemodialysis. Information about peritoneal dialysis is unavailable. This label statement differs from selected expert strategies for prolonged treatment with monitoring; it does not establish that those strategies apply to every patient.

RDM33-rxlist-linezolid-C1 · Source locator: Clinical pharmacology: renal impairment and hemodialysis.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/zyvox-drug/
Retrieved
2026-09-07
Renal-function method
Renal impairment categories; no numeric cutoff for label adjustment.
Source date/version
Revised July 2023
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
687ca905e4318ddf5b05a5ed74b75c62007b75a8a4ea47eb15377f31f75272e4
Rxlist

GlobalRPh RX List - ZYVOX

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Linezolid - ZYVOX renal label; selected renal source sections only, not a complete prescribing monograph.

Renal method: Qualitative renal impairment; no numeric dose algorithm is inferred.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Parent linezolid pharmacokinetics do not require renal dose adjustment, but inactive metabolites accumulate as renal function worsens; weigh the uncertain clinical significance against potential risks. The label directs administration after hemodialysis and reports approximately 30% removal in the described three-hour session. Peritoneal-dialysis pharmacokinetics are unavailable. This no-adjustment statement does not eliminate toxicity surveillance.

RDM47-rxlist-linezolid-d16c509512-C1 · Source locator: Clinical Pharmacology: Renal Impairment, lines 548-555.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/zyvox-drug/
Retrieved
2026-09-08
Renal-function method
Qualitative renal impairment; no numeric dose algorithm is inferred.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
9e9cfc6d10999071b1d02c66f26f5100b8420e36d84c6ad40f3e1b57b9e24c90
Separate professional-source layer

University and professional protocols

Professional

Nebraska Medicine: Linezolid

Open original reference

Open / share this exact local source

UNMC / Nebraska Medicine · CRRT/PIRRT statement only; select the indication-specific baseline dose separately.

Renal method: Not specified in this summary.
Source date: Not established
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

Renal-replacement statement

Linezolid is listed among agents not requiring adjustment specifically for CRRT/PIRRT.

linezolid:unmc-crrt-statement-linezolid-1 · Source locator: PDF page 2: no-adjustment list

Source identity and provenance
Source
https://www.unmc.edu/intmed/_documents/id/asp/final_crrt_pirrt_abxrecommendations_2023.pdf
Retrieved
2026-09-05
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
73d43752d92d45630cac28d8b32244561938e0cf51efe7fb84ee1f0454dbe482
Professional

UCSF - linezolid: standard dose and optional expert reduction

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Usual adult treatment is 600 mg IV or orally every 12 hours without routine renal adjustment; the hemodialysis table retains that regimen. Mycobacterial infection uses a separate 600 mg daily regimen.

For clinically stable patients with CrCl <30 mL/min and anticipated therapy longer than 10 days, some experts consider 300 mg twice daily after the first 72 hours to lower thrombocytopenia risk. This is an optional specialist-guided strategy, not a universal renal dose. Therapeutic drug monitoring may help; involve infectious diseases/pharmacy.

RDM30-018-linezolid-1 · Source locator: UCSF - linezolid: standard dose and optional expert reduction; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/linezolid
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
8e262bea091d636586d5af87ee33b56cb6ce884096a3590b47fd80caa61167e5
Professional

Linezolid - UCSF qualified renal guidance

Open original reference

Open / share this exact local source

University of California San Francisco, Infectious Diseases Management Program · Linezolid - UCSF qualified renal guidance; selected renal source sections only, not a complete prescribing monograph.

Renal method: Creatinine clearance (CrCl), mL/min; selected passage does not establish an estimating equation.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-08

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

UCSF generally lists 600 mg IV or orally every 12 hours without renal adjustment. For clinically stable patients with CrCl <30 mL/min and an anticipated course longer than 10 days, some experts consider 300 mg every 12 hours after the first 72 hours to reduce thrombocytopenia risk; therapeutic drug monitoring and ID/pharmacy consultation may assist. Its hemodialysis table retains 600 mg every 12 hours. This qualified expert option is not a universal renal reduction or a replacement for indication-specific regimens.

RDM47-professional-linezolid-3405ad41c5-C1 · Source locator: Adult non-dialysis table and footnote, lines 15-24.

Source identity and provenance
Source family
professional_guidance
Source
https://idmp.ucsf.edu/content/linezolid
Retrieved
2026-09-08
Renal-function method
Creatinine clearance (CrCl), mL/min; selected passage does not establish an estimating equation.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
ea677c17490df64784a1688967d032d97ad825aa8e97c28f7e62c29c6c0578fb

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 2 RX List, 3 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/linezolid/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
31b1ec4543e8df6c4f7c7528c8e3a163c6ab03a401abfe1a6fb27cff5d56f0d1
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report